Kaiser Pharmaceuticals-B (02171.HK): Clinical Phase II trials of Surojelone Injection, a China-confirmed drug, have completed enrollment.

Gelonghui Finance · Aug 18 20:05

On August 19th, Keji Pharmaceuticals-B (02171.HK) announced that the confirmatory phase II clinical trial of Shuruijiaolunsai injection (research and development code: CT041, a targeted Claudin18.2 autologous CAR-T cell candidate product) conducted in China has completed enrollment and randomization according to the clinical protocol. The trial is an open-label, multicenter, randomized controlled clinical trial conducted in China to evaluate the efficacy and safety of Shuruijiaolunsai injection in the treatment of advanced gastric cancer/esophageal gastric junction adenocarcinoma patients who are Claudin18.2 positive and have had at least two treatment failures, with the primary endpoint being progression-free survival (PFS) evaluated by an independent review committee (IRC), and the control group being researcher-selected treatment (including paclitaxel, docetaxel, irinotecan, apatinib, or ramucirumab).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

科济药业-B(02171.HK)：舒瑞基奥仑赛注射液中国确证性II期临床试验已完成入组

Kaiser Pharmaceuticals-B (02171.HK): Clinical Phase II trials of Surojelone Injection, a China-confirmed drug, have completed enrollment.

Risk Disclaimer

Statement